** Brokerage Evercore ISI says Johnson & Johnson's JNJ.N Q4 medtech revenue was generally in line with estimates "with strength in vision/hips offset by softer electrophysiology and advanced surgery"
** J&J reports medtech Q4 revenue of $8.19 bln vs analysts' estimates of $8.22 bln
** Brokerage says co's Q4 U.S. organic revenue growth of 2.1% in its electrophysiology $(EP)$ segment is "soft", says share losses to Boston Scientific BSX.N and Medtronic MDT.N from their ongoing PFA launches "will be a focus"
** A pulsed field ablation system (PFA) is a type of heart device to treat certain abnormal heart rhythm conditions
** Medical device maker Abbott ABT.N also reported Q4 organic sales growth of 8.8% in its EP segment, which Evercore says "seems to be holding slightly better" than J&J
** Brokerage adds J&J's soft growth in its spine segment bodes well for other device makers Stryker SYK.N, Zimmer Biomet ZBH.N, Enovis ENOV.N and Medtronic
** J&J fell 7.7% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。